Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB Regular (also known as BB Regular Drop) is a medical cannabis flower product line distributed by the German pharmaceutical company DEMECAN and cultivated by Banner Brands in Canada. The product line features un-irradiated cannabis flowers with a high tetrahydrocannabinol (THC) content (typically around 25%) and low cannabidiol (CBD) content (approximately 1%). It includes specific cultivars such as Prodigy (a cross of Louie XIII OG and Moonbow #112 F2) and Crossbow (a cross of Moonbow #75 and Planet Purple F2). BB Regular is prescribed for inhalation or oral administration (e.g., as tea) to treat conditions such as chronic pain, sleep disorders (insomnia), anxiety, depression, and appetite loss. The therapeutic effects are primarily mediated by the activation of cannabinoid receptors CB1 and CB2 by THC, alongside modulation by CBD and various terpenes like beta-myrcene, limonene, and alpha-humulene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BB Regular.